Scanning Biotech Equities -- Agenus, Amicus Therapeutics, Peregrine Pharma, Vanda Pharma, and Acorda Therapeutics
LONDON, March 12, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Investor-Edge has initiated coverage on the following equities: Agenus Inc. (NASDAQ: AGEN), Amicus Therapeutics Inc. (NASDAQ: FOLD), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), and Acorda Therapeutics Inc. (NASDAQ: ACOR). Free research report on Agenus can be accessed at http://get.Investor-Edge.com/pdf/?c=Agenus&d=12-Mar-2015&s=AGEN. On Wednesday, March 11, 2015, the NASDAQ Composite ended at 4,849.94, down 0.20%, the Dow Jones Industrial Average declined 0.16%, to finish the day at 17,635.39, and the S&P 500 closed at 2,040.24, down 0.19%. The losses were broad based as seven out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 819.35, down 0.04%, while the index has advanced 1.64% in the previous three months. Register for your complimentary reports at the links given below.
Agenus Inc.'s stock finished Wednesday's session 3.45% higher at $5.40. A total of 0.96 million shares were traded, which was below its three months average volume of 2.17 million shares. The stock moved between $5.12 and $5.45 during the session. Over the last one month and the previous three months, Agenus Inc.'s shares have surged 9.53% and 71.43%, respectively. Additionally, the stock has gained 29.19% in the past one year. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $4.96 is greater than its 200-day moving average of $3.61. Agenus Inc.'s stock has a Relative Strength Index (RSI) of 54.34. Sign up and read the free notes on AGEN at:
http://get.Investor-Edge.com/pdf/?c=Agenus&d=12-Mar-2015&s=AGEN
On Wednesday, shares in Amicus Therapeutics Inc. fluctuated between $8.73 and $9.39 before ending the session 5.32% higher at $9.31. The stock reported a trading volume of 1.83 million shares, above its three months average volume of 1.46 million shares. Amicus Therapeutics Inc.'s shares have rallied 14.80% in the last one month, 16.81% in the previous three months and 327.06% in the last one year. The stock is trading above its 50-day and 200-day moving averages of $8.27 and $6.13, respectively. Moreover, shares of Amicus Therapeutics Inc. have an RSI of 59.33. The complimentary notes on FOLD can be downloaded as in PDF format at:
http://get.Investor-Edge.com/pdf/?c=Amicus%20Therapeutics&d=12-Mar-2015&s=FOLD
Peregrine Pharmaceuticals Inc.'s stock advanced 2.14%, to close the day at $1.43. The stock recorded a trading volume of 1.29 million shares, above its three months average volume of 1.21 million shares. The stock oscillated between $1.34 and $1.44 during the session. Over the last three months and over the past one year, Peregrine Pharmaceuticals Inc.'s shares have declined 4.03% and 37.00%, respectively. However, the stock has surged 14.40% in the previous month. The company's shares are trading above their 50-day moving average of $1.36, while the 50-day moving average is below Peregrine Pharmaceuticals Inc.'s 200-day moving average of $1.52. Additionally, the stock has an RSI of 51.36. Register for free on Investor-Edge and access the latest research on PPHM at:
http://get.Investor-Edge.com/pdf/?c=Peregrine%20Pharma&d=12-Mar-2015&s=PPHM
On Wednesday, shares in Vanda Pharmaceuticals Inc. recorded a trading volume of 0.91 million shares, higher than its three months average volume of 0.85 million shares. The stock ended the day at $10.61, which was 1.24% above its previous day's closing of $10.48, and registered an intraday range of $10.07 and $10.76. Although Vanda Pharmaceuticals Inc.'s shares have advanced 1.34% in the previous three trading sessions, it has lost 12.53% in the last one month and 30.01% in the past one year. The stock is trading below its 50-day and 200-day moving averages of $12.05 and $12.47, respectively. Furthermore, shares of Vanda Pharmaceuticals Inc. have an RSI of 38.75. The complete research on VNDA is available for free at:
http://get.Investor-Edge.com/pdf/?c=Vanda%20Pharma&d=12-Mar-2015&s=VNDA
Acorda Therapeutics Inc.'s stock edged 0.71% lower, to close Wednesday's session at $35.18, after oscillating between $34.73 and $35.97. The stock recorded a trading volume of 0.67 million shares, below its three months average volume of 0.74 million shares. Over the last one month and the previous year, Acorda Therapeutics Inc.'s shares have lost 4.64% and 5.86%, respectively. However, the stock has gained 1.27% in the last three trading sessions. The company's shares are trading above their 200-day moving average. The stock's 50-day moving average of $39.54 is above its 200-day moving average of $34.95. Further, Acorda Therapeutics Inc.'s stock traded at a PE ratio of 51.15 and has an RSI of 42.69. Free in depth research on ACOR is available at:
http://get.Investor-Edge.com/pdf/?c=Acorda%20Therapeutics&d=12-Mar-2015&s=ACOR
About Investor-Edge.com
At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Investor-Edge
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article